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Background: Emergence of multidrug resistance in Enterobacteriaceae limits the selection of antimicrobials for
treatment of infectious diseases. Identification of NDM-1 makes more difficulty in treating multidrug-resistant
Enterobacteriaceae infections. Carbapenem-resistant Escherichia coli clinical isolates from a tertiary hospital in
Wenzhou, east China, were investigated for NDM-1 production.
Results: The two tested isolates were negative for modified Hodge test, but positive for a double-disc synergy test
used for detecting metallo-β-lactamase production. E. coli WZ33 and WZ51 exhibited discrepant-level resistance to
most clinically frequent used antimicrobials, but still susceptible to trimethoprim/sulfamethoxazole, amikacin,
fosfomycin, tigecycline and polymyxin B. E. coli WZ33 and WZ51 were positive for blaNDM-1 determined by PCR and
DNA sequencing. Other than blaNDM-1, E. coli WZ33 also harbored blaCTX-M-14 and blaCMY-42, while E. coli WZ51
simultaneously harbored blaSHV-12, blaCTX-M-14 and blaCMY-42. Carbapenem resistance for E. coli WZ51 and WZ33 could
not be transferred to E. coli recipients through conjugation, but could be transferred to E. coli recipients by chemical
transformation. The EcoR1-digested DNA pattern of plasmids from the transformant of E. coli WZ51 was different
from that of E. coli WZ51. MLST showed that E. coli WZ33 and WZ51 belonged to an animal-associated clone
(ST167).
Conclusion: The present study is the first report of blaNDM-1 carriage in E. coli ST167 isolates and coexistence of
blaNDM-1 and blaCMY-42 in same isolate. Systemic surveillance should focus on the dissemination of blaNDM-1 among
Enterobacteriaceae, especially E. coli ST167 clone associated with animal infection.Background
Enterobacteriaceae, particularly Escherichia coli and
Klebsiella pneumioniae, are common pathogens causing
nosocomial infections. Multidrug resistance (MDR) for
Enterobacteriaceae has been increasing rapidly and
limits the selection of antimicrobials for empiric treat-
ment of infections caused by these organisms, which is
becoming a threat to public health [1]. Carbapenems are
the choice for the treatment of infections caused by
MDR Enterobacteriaceae, especially extended-spectrum
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stated.(pAmpC)-producing organisms. However, worldwide
emergence of carbapenem resistance challenges the treat-
ment of severe infections using carbapenems [1]. Carbape-
nemases, particularly the Ambler class A K. pneumoniae
carbapenemases (KPCs) and the Ambler class B metallo-
β-lactamases (MBLs), were mainly associated with carba-
penem resistance among Enterobacteriaceae [2]. The genes
encoding these carbapenemases are commonly located on
large mobile plasmids with other determinants conferring
resistance to other class antimicrobials, which facilitates the
transfer of MDR to other organisms [1]. KPC-2 is found to
be predominant carbapenemase among Enterobacteriaceae
[2]. IMP- and VIM-type MBLs were another frequently
described carbapenemases in Enterobacteriaceae world-
wide [3]. Importantly, in 2009, a novel MBL, named New
Delhi metallo-β-lactamase-1 (NDM-1), was identified in aLtd. This is an Open Access article distributed under the terms of the Creative
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infection who had returned to Sweden from India [4]. Since
the first report of NDM-1, this important carbapenemase
was found among many species of Gram-negative rods
from several countries [5-10], which has been becoming as
a major public health threat and represents a new challenge
for the treatment of infectious diseases. In China, NDM-1
was first identified in 4 clonally unrelated Actinetobacter
baumannii isolates [11]. Subsequently, it was found among
non-baumannii Acinetobacter spp. from China [12-14].
Although NDM-1 was initially found among Enterobacteri-
aceae, it has not be described in these organisms until
recently in China [15,16].
Our previous study described two clonally unrelated
K. pneumoniae isolates harboring blaNDM-1 from two
teaching hospitals in Nanchang, central China [16]. In
the present study, we identified blaNDM-1 among two
clonally related E. coli isolates belonging to ST167 from
one tertiary hospital in Wenzhou, east China, among
which blaNDM-1 was found to coexist with blaCTX-M-14
and blaCMY-42.
Methods
Isolation and identification of bacterial strains
Clinical samples for microbiological examination were
carefully collected by sterile containers without contam-
ination with commensals or from external sources. Be-
fore the collection of sputum samples, patients should
wash oral cavity three times using sterile physiological
saline. When collecting urine samples, the meatus urinar-
ius must be washed thoroughly for avoiding the contam-
ination by colonizing bacteria and mid-stream urine was
collected in sterile container for bacterial culture. After
collection, clinical samples were transported immediately
to clinical laboratory for microbiological examination.
Sputum samples observed <10 squamous cells and >25
white blood cells per visual field under microscope with
100 times magnification were qualified for bacterial
culture. The qualified samples were inoculated on blood
agar plate for the isolation of bacteria in accordance with
routine procedure. The bacterial isolates from sputum
samples with amount of >107 CFU/ml and from urine
samples with amount of >105 CFU/ml by quantitative
culture were considered to be responsible for infection.
Identification of bacterial isolates was performed using
Vitek-2 automated microbiology analyzer (bioMe’rieux,
Marcy l’Etoile, France) according to the manufacturer’s
instructions. Staphylococcus aureus ATCC25923 and
E. coli ATCC 25922 were used as quality control strains
for bacterial identification. Written informed consent for
participation in the study was obtained from participants.
The Ethics Committee of the first Affiliated Hospital of
Wenzhou Medical University exempted this study from
review because the present study focused on bacteria.Antimicrobial susceptibility testing
Antimicrobial susceptibility test was performed initially
using Gram-negative susceptibility (GNS) cards on the
Vitek system (bioMe’rieux, Marcy l’Etoile, France). The
E-test method was used for further determination of
minimum inhibitory concentrations (MICs) of clinically
important antimicrobial agents for clinical isolates and
their transformants, in accordance with manufacturer’s
instructions. Antimicrobials evaluated included ampicil-
lin, amikacin, gentamicin, levofloxacin, piperacillin,
piperacillin/tazobactam, cefotaxime, ceftazidime, cefepime,
aztreonam, cefoxitin, imipenem, meropenem, ertapenem,
tigecycline, polymyxin B, fosfomycin and trimethoprim/
sulfamethoxazole. Results of susceptibility testing were
interpreted in accordance with the criteria recommended
by Clinical and Laboratory Standards Institute (CLSI) [17].
S. aureus ATCC25923 and E. coli ATCC 25922 were used
as quality control strains for susceptibility testing.
Detection of β lactamase production
The modified Hodge test (MHT) was performed on a
Mueller-Hinton agar plate with ertapenem as substrate
and E. coli ATCC 25922 as the indicator organism for
detection of carbapenemases as described previously [17].
A double-disc synergy test was designed for detecting
MBLs as described previously [18]. Briefly, imipenem and
combined imipenem with EDTA (750 μg) disks were
placed on the agar plates with the tested isolates. After
over-night incubation at 35°C, if inhibition zone diameter
of the imipenem with EDTA disk increases ≥6 mm relative
to imipenem disk, the test is considered positive. ESBL
production was determined by the CLSI-recommended
confirmatory double disk combination test [17]. Isolates
were tested for AmpC activity by a three-dimensional
extract method as described previously [19].
Detection of antimicrobial resistance determinants
Potential antimicrobial resistance determinants including
carbapenemase genes, ESBL genes, plasmid-mediated
AmpC genes and plasmid-mediated quinolone resistance
determinants were investigated using the polymerase chain
reaction (PCR) and nucleotide sequencing, employing
previously published primers [20-24]. Plasmid Midi kits
(Qiagen, Hilden, Germany) were used to extract plasmid
DNA from donors and transformants according to the
manufacturer’s instructions. Plasmid DNA of transfor-
mants was digested by EcoR1 according to manufacturer’s
instructions. 10 μl of each digestion mixture was subjected
to electrophoresis on 1.0% agarose gels, stained with
ethidium bromide, and photographed under UV light.
Transferability of plasmids with carbapenem resistance
In order to determine whether carbapenem resistance was
transferable in E. coli isolates, a conjugation experiment
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recipient as previously described [25]. Transconjugants
were selected on tryptic soy agar plates containing sodium
azide (100 μg/ml) for counterselection, and imipenem
(0.5 μg/ml) for plasmid-mediated carbapenem resistance
selection. Standard heat-shock transformation of chemically
competent bacteria was applied to transfer carbapenem
resistance. Briefly, 5 μl of DNA (25 ng) was mixed into 50
μl of competent cells (E. coli DH5α) in a microcentrifuge
tube. After placing competent cells and DNA mixture on
ice for 30 min, 2/3 of the tube was placed into a 42°C water
bath for 45 seconds. The tube was put back on ice for 2
min. 500 μl of Luria-Bertani media without antibiotic was
added into the tube and the mixture grew in 37°C shaking
incubator for 45 min. All of the transformation were plated
onto Luria-Bertani agar plates containing imipenem (0.5
μg/ml) and incubated at 37°C overnight.
Multi-locus sequence typing (MLST)
MLST were performed on E. coli isolates positive for
blaNDM-1 using amplification of internal fragments of
the seven housekeeping genes of E. coli according to the
E. coli MLST website (http://mlst.ucc.ie/mlst/dbs/Ecoli).
Results and discussion
Bacterial isolation and patients’ information
In August, 2012, E. coli WZ33 with carbapenem resistance
was isolated from urine of a 43-year–old female patient
with infectious symptoms at the First Affiliated Hospital of
Wenzhou Medical University (FAHWMU) in Wenzhou,
central China. FAHWMU is the largest comprehensive
hospital with 3000 beds in Wenzhou. On July 11, 2012, the
patient diagnosed with acute myelitis was admitted to
FAHWMU. After hospitalization, she was subjected to
urethral catheterization. Subsequently, she appeared in-
fectious symptoms on July 20, with the highest body
temperature of 39.5°C. Urine and blood of the patient
were collected on July 20 and 21 for microbiological
culture. A carbapenem-susceptible E. coli isolate with only
resistance to ampicillin, gentamycin, tobramycin and
trimethoprim/sulfamethoxazole was isolated from urine
sample, while another carbapenem-susceptible E. coli
isolate with same resistance profiling as that of the isolate
from urine sample was isolated from blood sample. The
patient’s symptoms improved following the treatment with
cefuroxime and ceftazidime via intravenous drip. On
August 6, urine sample was collected for microbiological
culture again. Surprisingly, a carbapenem-resistant E. coli
isolate with pure growth, named E. coliWZ33, was isolated
from urine sample. After subjected to be treated with
antimicrobials for 5 days, the symptoms of the patient
disappeared and she was discharged from the hospital.
The other carbapenem-resistant isolate E. coliWZ51 was
isolated from the sputum of a 66-year-old male patientswith pulmonary infection at FAHWMU. Before admitted
to FAHWMU, the patient was hospitalized at another
comprehensive hospital away from FAHWMU about 30
kilometers for anti-infection therapy using levofloxacin.
After hospitalization at FAHWMU on March 19, the
patient was subjected to treatment of pulmonary infection
using ceftazidime via intravenous drip. On March 20,
sputum sample was collected for bacterial culture and
carbapenem-resistant isolate, E. coliWZ51, was identified
later. After subjected to be treated with ceftazidime for 4
days, the symptoms of the patient disappeared.
Antimicrobial resistance determinants
As both E. coli WZ33 and WZ51 were resistant to
third-generation cephalosporin and carbapenems, MHT
was performed to determine the production of carbape-
nemases. Unexpectedly, both tested isolates were MHT
negative. For further investigation on carbapenemase
production, a double-disc synergy test was used for
detecting the MBL production. As expected, both tested
isolates were found to produce MBLs. The genes encod-
ing carbapenemases, including blaVIM, blaIMP, blaSPM-1,
blaGIM-1, blaSIM-1 and blaNDM-1, were further investi-
gated by PCR and DNA sequencing. Two carbapenem-
resistant isolates with carbapenemase production, E. coli
WZ33 and WZ51, were positive for blaNDM-1. The
MHT has an excellent sensitivity for detecting entero-
bacterial isolates producing KPC- and OXA-48-type
carbapenemases, but has low sensitivity for the detec-
tion of NDM-1 producers [26]. Previous study reported
that negative or weakly positive MHT results were
observed for 11 of 15 NDM-1-producing strains [27].
Two NDM-1-producing K. pneumonia clinical isolates
reported by our previous study were also MHT negative
[16]. In the present study, two NDM-1-producing E. coli
isolates were also negative for MHT. The false negative
results of MHT in NDM-1-producing isolates may be
caused by the production of some substances that can
inhibit growth of E. coli ATCC25922 and low produc-
tion of NDM-1 [27]. False positive results of carbapene-
mase production by the MHT among isolates with
resistance or reduced susceptibility to carbapenem
result from low-level carbapenem hydrolysis by CTX-M
type ESBLs and ESBL production coupled with porin
loss [28,29]. These data mentioned above indicated that
the detection of carbapenemases by the MHT was
challenged, especially the detection of NDM-1. NDM-1
was mainly found in Enterobacteriaceae in south Asia,
Europe and America [5,6,30]. In contrast, it was initially
and mainly described in Actinetobacter spp. clinical
isolates in China [11-14], even emergence of dissemin-
ation of NDM-1-producing A. pittii (27 isolates) in an
intensive care unit [31]. Recently, a higher isolation of
NDM-1-producing A. baumannii from the sewage of
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described, indicating that the hospital sewage may be
one of the diffusion reservoirs of NDM-1 producing
bacteria [32]. However, one screening effort revealed
no blaNDM-1 expression among 3439 E. coli and 2840
K. pneumoniae isolates from 57 hospitals representing
18 provinces in China [11]. Recently, blaNDM-1 began to
emerge in Enterobacteriaceae from China [15,16,33].
Two clonally unrelated K. pneumoniae isolates from two
teaching hospitals in Nanchang, central China, were found
to harbor blaNDM-1 [16]. Coexistence of blaNDM-1 and
blaIMP-26 was identified among a carbapenem-resistant
Enterobacter cloacae clinical isolate from southwest China
[33]. Sporadic emergence of blaNDM-1 in E. coli clinical
isolates in the present study further corroborates the evi-
dence that blaNDM-1 carriage extends beyond Actinetobac-
ter spp into Enterobacteriaceae in China. Another study
from China also found that a E. coli clinical isolate isolated
from the ulcer secretion of patient with diabetes-related
foot complications harbored blaNDM-1 [15]. International
travelers to the Indian subcontinent, are prone to acquire
the infections caused by NDM-1-producing organisms
[4,5]. However, the two patients harboring NDM-1-
producing E. coli had never traveled to outside China.
Antimicrobial susceptibility profiling
The results of antimicrobial susceptibility of E. coli WZ33
and WZ51 are listed in Table 1. Both tested isolates wereTable 1 MIC values of antimicrobials for E.coli isolates carryin
Antimicrobials
















polymyxin B 1.5 0.38
tigecycline 0.19 0.5
Fosfomycin 0.5 0.25
a, transformant.multi-resistant to clinically frequently used antimicrobials,
including ampicillin, piperacillin, piperacillin/tazobatam,
cefotaxime, ceftazidime, cefepime, cefoxitin, aztreonam,
imipenem, meropenem, ertapenem and gentamicin, levo-
floxacin, but susceptible to trimethoprim/sulfamethoxa-
zole, amikacin, fosfomycin, tigecycline and polymyxin B.
Most of NDM-1-producing isolates were highly resistant
to clinically available antibiotics except to tigecycline and
colistin [4].
Co-production of carbapenemases with other β-
lactamases including ESBLs and pAmpCs results in
resistance to nearly all clinically available β-lactams. As
both E. coli WZ33 and WZ51 were highly resistant to all
tested β-lactams, other β-lactamases other than NDM-1
were investigated. Although a ESBL gene blaCTX-M-14
was identified in E. coli WZ33 and two ESBL genes,
blaCTX-M-14 and blaSHV-12, were found in E. coli WZ51,
ESBL production was not detected in these two isolates,
determined by CLSI-recommended double-disk test.
As carbapenemases and AmpCs are not inhibited by
clavulanic acid, co-production of ESBLs, AmpCs and
carbapenemases can mask determination of ESBLs
using the CLSI-recommended double-disk test [17].
Both E. coli WZ33 and WZ51 were highly resistant to
cefoxitin (MICs ≥ 256), which was indicative of AmpC
production. As expected, two tested isolates were found
to harbor pAmpC gene blaCMY-42 in accordance with
phenotypic results determined by three-dimension test.g blaNDM-1 and their transformants
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Figure 1 EcoR1-digested DNA patterns of plasmids from the
transformants of E. coli WZ33 and WZ51. M, the DNA ladder; A,
Digest of plasmid from the transformant of E.coli WZ33; B, Digest of
plasmid from the transformant of E.coli WZ51.
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The present study is the second report of blaCMY-42.
However, it is the first report of the coexistence of
blaCMY-42 and blaNDM-1.
Transferability of resistance plasmids carrying blaNDM-1
blaNDM-1 was found to be located on the plasmids with
different size and genetically diverse background and
disseminated among different species of organisms by
the transfer of resistance plasmids [1,5]. The plasmids
conferring carbapenem resistance for E. coli WZ33 and
WZ51 were not successfully self-transferred into the
recipient E. coli J53 using filter mating conjugation by
repeat attempts. But the plasmids conferring carba-
penem resistance for both E. coli WZ33 and WZ51
could be transferred into the recipient (E. coli DH5α)
using chemical transformation. WZ33 contained 2 plas-
mids (approximately 65- and 3-kb). WZ51 contained 3
plasmids with sizes of approximately 65-, 7- and 3-kb).
The transformants each contained a single blaNDM-1-
bearing plasmid with size of approximately 65 kb.
The transformant from E. coli WZ51 was positive for
blaNDM-1 and blaSHV-12, while the transformant from
WZ33 carrying only the NDM gene was susceptible to
aztreonam, which is characteristic of MBLs.
The transformants of two tested isolates showed
increased MICs for antimicrobials relative to the recipi-
ents (E. coli DH5α) (Table 1). The plasmids with carba-
penem resistance in E. coli WZ33 and WZ51 exhibited
discrepant MICs for antimicrobials, indicating that the
two plasmids may be different kind of plasmids. As
expected, the EcoR1- digested DNA pattern of plasmids
from the transformant of E. coli WZ33 was different
from that for E. coli WZ51 (Figure 1). Connections
between sequence types and plasmid replicons are
potentially important. K. pneumoniae ST14 clone
was found to be important for the dissemination of
blaNDM-1 [35].
Genotype of the tested isolates
MLST typing revealed that both E. coli WZ33 and
WZ51 belonged to ST167, indicating that they were
clonally related. E. coli isolates belonging to ST167
have not been reported before in China. To our best of
knowledge, this is the first report of E. coli ST167 clone
in China and NDM-1 in E. coli ST167 clone. These two
genetically related isolates carried different plasmids
carrying blaNDM-1, indicating that E. coli WZ33 and
WZ51 acquired blaNDM-1-carrying plasmids by differ-
ent ways. ST167 was found to be prevalent ST among
ESBL-producing E. coli isolates from animals [36,37].
This clone is rare in clinical isolates. We did not know
whether E. coli WZ33 and WZ51 were from animals
and further investigation should be executed. Recently,a novel NDM carbapenemase variant, NDM-7, was
identified in a E. coli clinical isolate belonging to
ST167 in France [38]. Therefore, emergence of NDM-
producing E. coli ST167 isolates should be of concern.Conclusions
In conclusion, the present study is the first report of
blaNDM-1 carriage in E. coli ST167 isolates and coexist-
ence of blaNDM-1 and blaCMY-42 in same isolate.
Systemic surveillance should focus on the dissemin-
ation of blaNDM-1 among Enterobacteriaceae, especially
E. coli ST167 clone associated with animal infection.Competing interest
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